Bioretec Ltd's business review January-September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage

Contributed by: PR Newswire

Tags

Bioretec-Review-2024

More Like This

Bioretec Ltd's half-year report January-June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results

Bioretec Ltd's business review January-March 2024: Controlled launch in the U.S. progresses

Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European Marketing Authorization

Inside information: Bioretec's European market authorization for RemeOs trauma screw has proceeded to expert panel evaluation, the approval is estimated during the Q2 2024

The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Inside information: Bioretec estimates that the approval of the European market authorization for the biodegradable RemeOs™ trauma screw will move to the first quarter of 2024

Bioretec Ltd's financial statements bulletin 2024: Foundation for future growth in 2024 - CE mark received in January 2025